newsfilter
← Latest News
PR Newswire·

Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates

Cohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Identify Potential Paths Forward for Pegzilarginase Gross Proceeds of $45 Million from May 2022 Registered Direct Offering Extend